Abstract: The disclosure provides compositions comprising exosome subpopulations, and methods of their use in subjects having certain disorders including lung disorders, cardiovascular disorders, renal disorders and ischemic neural disorders.

Abstract: The disclosure provides compositions comprising exosome subpopulations, and methods of their use in subjects having certain disorders including lung disorders, cardiovascular disorders, renal disorders and ischemic neural disorders.

Abstract: The disclosure provides compositions comprising exosome subpopulations, and methods of their use in subjects having certain disorders including lung disorders, cardiovascular disorders, renal disorders and ischemic neural disorders. The disclosure provides compositions comprising exosomes and methods of use thereof in the treatment and/or prevention of various diseases or disorders. 25 Accordingly, one aspect of the disclosure provides an isolated exosome. In some embodiments, the isolated exosome comprises one or more markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3, SMAD5 and CD105, and/or the isolated exosome does not comprise one or more markers selected from the group consisting of FLOT1, CD9, CD81, CAV1, EGFR, AKT1 and AKT2. In some embodiments, 30 the isolated exosome comprises 2, 3, 4, 5, 6, 7 or 8 markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3>SMAD5 and CD105.

Abstract: The disclosure provides compositions comprising exosome subpopulations, and methods of their use in subjects having certain disorders including lung disorders, cardiovascular disorders, renal disorders and ischemic neural disorders. The disclosure provides compositions comprising exosomes and methods of use thereof in the treatment and/or prevention of various diseases or disorders. 25 Accordingly, one aspect of the disclosure provides an isolated exosome. In some embodiments, the isolated exosome comprises one or more markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3, SMAD5 and CD105, and/or the isolated exosome does not comprise one or more markers selected from the group consisting of FLOT1, CD9, CD81, CAV1, EGFR, AKT1 and AKT2. In some embodiments, 30 the isolated exosome comprises 2, 3, 4, 5, 6, 7 or 8 markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3>SMAD5 and CD105.